MedLogic Global Corporation Awarded ISO 9001 Certification and ISO 9002 Re-Certification

Business Wire, Jan 25, 2000

Business Editors/Health &Medical Writers

COLORADO SPRINGS, Colo.--(BW HealthWire)--Jan. 25, 2000

MedLogic Global Corporation, a developer and manufacturer of medical adhesives, announced today that it was awarded ISO 9001 certification for its Colorado Springs facility and has received ISO 9002 re-certification for both its Colorado Springs and Plymouth, England operations. The ISO 9000 series of designations are awarded to organizations that demonstrate the highest standards of design, development, manufacturing and quality control. The International Organization for Standardization (ISO), with a membership of more than 110 countries, facilitates the development of international standards and guidelines to ensure product and service standardization for the global marketplace.

&uot;The ISO 9001 certification and ISO 9002 re-certifications represent significant achievements for MedLogic,&uot; said Michael M. Byram, President and CEO of MedLogic Global Corporation. &uot;The validation of our design, development and manufacturing practices reflects MedLogic's performance in achieving excellence in developing and delivering quality products to the medical community.&uot;

MedLogic's product portfolio of medical adhesives and glues balance strength and flexibility, providing clinicians and patients with optimally performing products unique in the industry. These products address a number of medical needs, including the closure of external cuts and wounds, the protection of surgical incision areas from bacteria during and after surgery, and the prevention of skin breakdown wounds caused by exposure to prolonged pressure or radiation therapy.

MedLogic recently announced a new $15 million equity infusion commitment from a consortium led by Citigroup Investments and Verus International LTD.

About MedLogic Global Corporation:

MedLogic Global Corporation develops, manufactures and markets advanced polymer-based medical-adhesives (wound glues), skin protectants, and sealants based on the Company's proprietary formulations of cyanoacrylate-based compounds. Included in the broad portfolio of products are LiquiBand(R), LiquiBand(R) Plus, LiquiDrape(TM), LiquiSeal(TM), LiquiSeal(TM) Plus, and LiquiShield(R). MedLogic is also pursuing the development of proprietary hydrogel polymer technologies which have the potential to be used in drug delivery applications.

This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words &uot;believes,&uot; &uot;expects,&uot; &uot;anticipates,&uot; or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of MedLogic Global Corporation to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above and MedLogic Global Corporation assumes no responsibility to update the information included herein for events occurring after the date hereof.

NOTE: MedLogic(R), LiquiBand(R), LiquiBand(R) Plus, and LiquiShield(R) are registered trademarks of MedLogic Global Corporation.